176 related articles for article (PubMed ID: 18524847)
41. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
[TBL] [Abstract][Full Text] [Related]
42. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
[TBL] [Abstract][Full Text] [Related]
43. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
Vredeveld LC; Possik PA; Smit MA; Meissl K; Michaloglou C; Horlings HM; Ajouaou A; Kortman PC; Dankort D; McMahon M; Mooi WJ; Peeper DS
Genes Dev; 2012 May; 26(10):1055-69. PubMed ID: 22549727
[TBL] [Abstract][Full Text] [Related]
44. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
45. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications.
Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA
J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796
[TBL] [Abstract][Full Text] [Related]
46. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
47. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Patel SP; Lazar AJ; Papadopoulos NE; Liu P; Infante JR; Glass MR; Vaughn CS; LoRusso PM; Cohen RB; Davies MA; Kim KB
Cancer; 2013 Feb; 119(4):799-805. PubMed ID: 22972589
[TBL] [Abstract][Full Text] [Related]
48. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
Brandi G; Tavolari S; De Rosa F; Di Girolamo S; Agostini V; Barbera MA; Frega G; Biasco G
PLoS One; 2012; 7(7):e41347. PubMed ID: 22911782
[TBL] [Abstract][Full Text] [Related]
49. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
50. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
51. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
52. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
53. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
[TBL] [Abstract][Full Text] [Related]
54. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
55. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
[TBL] [Abstract][Full Text] [Related]
56. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
57. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
58. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
59.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
60. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
